Literature DB >> 21212015

Synthesis, characterization, antibacterial activity, SOD mimic and interaction with DNA of drug based copper(II) complexes.

Mohan N Patel1, Promise A Dosi, Bhupesh S Bhatt, Vasudev R Thakkar.   

Abstract

Novel metal complexes of the second-generation quinolone antibacterial agent enrofloxacin with copper(II) and neutral bidentate ligands have been prepared and characterized with elemental analysis reflectance, IR and mass spectroscopy. Complexes have been screened for their in-vitro antibacterial activity against two Gram(+ve) Staphylococcus aureus, Bacillus subtilis, and three Gram((-ve)) Serratia marcescens, Escherichia coli and Pseudomonas aeruginosa organisms using the double dilution technique. The binding of this complex with CT-DNA has been investigated by absorption titration, salt effect and viscosity measurements. Binding constant is ranging from 1.3×10(4)-3.7×10(4). The cleavage ability of complexes has been assessed by gel electrophoresis using pUC19 DNA. The catalytic activity of the copper(II) complexes towards the superoxide anion (O2.-) dismutation was assayed by their ability to inhibit the reduction of nitroblue tetrazolium (NBT). Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21212015     DOI: 10.1016/j.saa.2010.11.056

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  2 in total

Review 1.  The Use of Copper as an Antimicrobial Agent in Health Care, Including Obstetrics and Gynecology.

Authors:  Linda P Arendsen; Ranee Thakar; Abdul H Sultan
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

2.  Efficient copper-based DNA cleavers from carboxylate benzimidazole ligands.

Authors:  Víctor A Barrera-Guzmán; Edgar O Rodríguez-Hernández; Naytzé Ortíz-Pastrana; Ricardo Domínguez-González; Ana B Caballero; Patrick Gamez; Norah Barba-Behrens
Journal:  J Biol Inorg Chem       Date:  2018-08-03       Impact factor: 3.358

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.